Margin performance in line with expectations: Jonathan Hunt, Syngene - Business News: Latest News & Videos about market and economy | Trendmergers

Breaking

Post Top Ad

Post Top Ad

Margin performance in line with expectations: Jonathan Hunt, Syngene

"Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufacture under licence from Gilead. That, of course, gave an additional boost in the quarter."

from Industry-Economic Times
Read The Rest:economictimes...

Post Top Ad